Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of ...

Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: ...

ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, November 12, 2024 /EINPresswire / -- GPN Vaccines Ltd is pleased to announce that dose escalation has been ap ...

Vaxcyte (NASDAQ:PCVX) announced that the U.S. FDA cleared the VAX-31 infant Investigational New Drug application and granted ...

A MEDICAL expert has a warning about a disease that is a “major cause of illness and death”, with one in ten people dying ...

But older adults are more at risk of having ... so it’s also important to start getting vaccinated around age 65. Pneumococcal polysaccharide vaccines (PPSV). PPSVs contain purified sugars ...

As the weather gets colder, the risk of pneumonia increases. KYW medical editor Dr. Brian McDonough has new vaccine recommendations to protect those at risk.

Analyst Thomas Shrader of BTIG maintained a Buy rating on Vaxcyte (PCVX – Research Report), retaining the price target of $160.00. Thomas ...

One expert says updated Covid-19 vaccines is important protect high-risk groups from severe respiratory infections, while two ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Pfizer Limited Managing Director Meenakshi Nevatia has reaffirmed the company dedication to India highlighting its extensive Make in India initiatives ...

Vaxcyte said its vaccine covers serotypes involved in around 95% of invasive pneumonia disease (IPD) cases in adults 50 and older in the US. It expects the pneumococcal vaccine market to reach a ...